Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non ‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea

ConclusionSequential afatinib and osimertinib treatment resulted in better survival rates than treatment with afatinib followed by other chemotherapies.

Source: Cancer Medicine - July 14, 2021 Category: Cancer & Oncology Authors: Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi ‐Hyun Kim, Sung Yong Lee, Cheol‐Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun J Tags: RESEARCH ARTICLE Source Type: research